Takeda

This study tests a dengue vaccine in adults aged 45 to 79, including those with diabetes, high blood pressure, or kidney disease. Participants receive two shots three months apart. Researchers will monitor side effects and measure the immune response to see if the vaccine works w…

This study monitors 275 people in Japan receiving darvadstrocel, a special cell injection, for complex anal fistulas caused by Crohn's disease. Researchers will track side effects and whether fistulas close over 36 months. The goal is to see if this treatment safely improves symp…

This study tests a drug called mezagitamab for people with IgA nephropathy, a kidney disease where the body's immune system damages the kidneys. The main goal is to see if the drug reduces protein in the urine, a sign of kidney damage. About 347 adults will receive either mezagit…

This study tests a new drug called elritercept against a standard treatment (epoetin alfa) for anemia caused by a bone marrow disorder called myelodysplastic syndromes (MDS). About 300 adults who need regular red blood cell transfusions will take part. The goal is to see if elrit…

This study looks back at medical records of 50 people in Saudi Arabia with hereditary angioedema (HAE) who have been taking Takhzyro (lanadelumab) for at least 6 months to prevent sudden swelling attacks. Researchers want to see if the drug reduces disease activity and improves q…

This study is for Indian adults with untreated stage 3 or 4 Hodgkin lymphoma. It tests how safe and effective a drug called brentuximab vedotin is when added to standard chemotherapy (AVD). Participants receive treatment for about 6 months and are monitored for side effects and c…

This program offers ongoing access to idursulfase-IT (TAK-609) for children and adults with Hunter syndrome who have cognitive impairment and completed earlier clinical trials. Participants receive the drug directly into the spinal fluid alongside their regular intravenous enzyme…

This study tests a new medicine called TAK-411 for people with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a condition where the immune system attacks nerve coverings, causing weakness and numbness. The goal is to see if TAK-411 can improve physical function…

This study tests a drug called maribavir in 20 Chinese adults who had a stem cell or organ transplant and have a CMV infection that no longer responds to standard treatments. The main goal is to see if maribavir is safe and tolerable, and also how well it clears the virus and pre…

This study tests a new drug called KER-050 (elritercept) in about 135 adults with myelofibrosis, a rare bone marrow cancer. The drug is given alone or with the standard treatment ruxolitinib. The main goals are to check safety and see if it helps with anemia and other symptoms. T…

This study follows 30 adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are switching to the treatment HyQvia. Researchers want to understand why patients chose this switch, how satisfied they are, and how the treatment affects their symptoms, daily…

This study tests a new daily pill, zasocitinib (TAK-279), for people with active psoriatic arthritis, a condition causing joint pain and skin patches. About 600 adults will receive either the drug or a placebo for up to 60 weeks to see if it improves symptoms like joint swelling …

This study monitors 25 people in Japan with Acquired Hemophilia A who receive OBIZER (Susoctocog Alfa) injections to control bleeding. Researchers will track side effects and how well the drug stops bleeding for up to 90 days after the last dose. The goal is to confirm the drug's…

This study looks at the long-term safety of a drug called vedolizumab in children and teenagers with ulcerative colitis or Crohn's disease. About 70 participants who responded well to the drug in an earlier study will continue treatment, while others will be monitored for up to 2…

This study watches how safe OBIZUR is for adults with acquired hemophilia A, a rare condition that causes sudden and severe bleeding. About 9 people will be followed as they receive the drug in regular medical practice. The goal is to track side effects and see how well the drug …

This study tests whether a monthly infusion of vonicog alfa (a lab-made clotting protein) can prevent bleeding episodes in 24 children with severe von Willebrand disease. Participants receive the treatment for 12 months and have 5 clinic visits. The main goal is to see if the ann…

This study tests a medicine called vedolizumab in children and teenagers with moderate to severe Crohn's disease. The goal is to see if the drug can keep symptoms under control and reduce gut inflammation over a year. Participants first receive three infusions over six weeks, the…

This program offers continued access to an unlicensed medicine called recombinant von Willebrand factor (rVWF) for children and adults with severe von Willebrand disease who have already benefited from it in a previous study. Participants must have completed at least 12 months of…

This study tests whether a drug called VONVENDI is safe and helps control bleeding in 20 Chinese adults with von Willebrand disease, a condition that makes blood clot poorly. Some participants may also receive ADVATE if needed. The study lasts about 14 months and includes clinic …

This study tests whether combining two drugs, vedolizumab and tofacitinib, can help adults with moderate to severe ulcerative colitis achieve remission. Participants receive both drugs for 8 weeks, then those who respond continue with vedolizumab alone for 44 weeks. The goal is t…

This study tests a new drug called TAK-330 to reverse the effects of blood thinners (Factor Xa inhibitors) in people who need urgent surgery. About 328 adults on these blood thinners will be randomly assigned to get TAK-330 or standard reversal treatment before their procedure. T…

This study follows 200 Chinese children and adults with Fabry disease who are receiving routine treatment with Replagal (agalsidase alfa). Researchers will track changes in heart and kidney function, quality of life, and safety over time. The goal is to see how well the enzyme re…

This study looks at the long-term safety of the drug vedolizumab in children with ulcerative colitis or Crohn's disease. It is for kids who already completed a previous study on this drug. Researchers will track side effects and major health events like infections or surgeries ov…

This study monitors adults with advanced ALK-positive non-small cell lung cancer who are starting brigatinib for the first time. Researchers will track side effects and measure how often tumors shrink or disappear. The goal is to confirm the drug's safety and effectiveness in eve…

This study tests an experimental drug called elritercept (KER-050) in 160 adults with a bone marrow condition called myelodysplastic syndromes (MDS) who have anemia. The main goals are to check the drug's safety and how well people tolerate different doses. Researchers will also …

This study follows 75 adults in Belgium who have had a stem cell or solid organ transplant and developed a CMV infection. Researchers will watch how doctors use the drug maribavir and how well it clears the virus, including side effects and whether the infection comes back. Parti…

This study looks at the long-term safety of an oral medication called zasocitinib (TAK-279) for people with moderate to severe Crohn's disease or ulcerative colitis. Participants who responded well to the drug in earlier studies can continue treatment for up to 3 years. The main …

This study is a survey in Japan of the drug Brigatinib for people with a specific type of non-small cell lung cancer. The main goal is to check for lung-related side effects over one year. About 500 participants will take the drug as part of their normal care, and doctors will re…

This study looks at how safe and effective the drug LIVTENCITY (Maribavir) is for treating cytomegalovirus (CMV) infection in adults who have had an organ or stem cell transplant. About 168 participants in South Korea will be followed for 20 weeks during their routine care. The g…

This study tests an experimental drug called fazirsiran in 160 adults with Alpha-1 antitrypsin deficiency who have moderate to severe liver scarring (fibrosis). Participants receive either fazirsiran or a placebo, and doctors measure changes in liver scarring and other markers ov…

This study tracks side effects of ADZYNMA (recombinant ADAMTS13) in 40 people with congenital thrombotic thrombocytopenic purpura (cTTP), a rare blood clotting disorder. Participants receive the drug as part of their regular care, and doctors monitor them for 18 months. The goal …

This study tests a drug called mezagitamab, given as a shot under the skin, in adults with chronic immune thrombocytopenia (ITP) — a condition where the immune system destroys platelets needed for clotting. The goal is to see if the drug can keep platelet counts stable over 6 mon…

This study tests a daily pill called zasocitinib in children and teens aged 4 to 17 with moderate-to-severe plaque psoriasis. The goal is to see if it safely clears or nearly clears skin patches. The trial lasts up to 4 years, with some participants starting on a placebo before s…

This study tracks side effects of the drug ADCETRIS (brentuximab vedotin) when used with standard chemotherapy in children and teenagers with untreated Hodgkin lymphoma. Researchers will monitor for serious side effects like bone marrow suppression, nerve damage, and lung problem…

This program provides children and teenagers with moderate to severe ulcerative colitis or Crohn's disease continued access to vedolizumab, a medication given through an IV. It is for those who completed a prior study and still benefit from the treatment, with no suitable alterna…

This study tests a medicine called fazirsiran for people with liver disease caused by Alpha-1 antitrypsin deficiency. The drug works by reducing the buildup of an abnormal protein in the liver that can lead to scarring and liver failure. About 50 adults with mild liver scarring w…

This study tests whether combining two drugs (vedolizumab with adalimumab or ustekinumab) works better than one for adults with moderate to severe Crohn's disease. In the first part, 100 participants get the dual therapy for 26 weeks. Those who respond then switch to vedolizumab …

This study looks at how well the drug brentuximab vedotin works after a stem cell transplant in adults with Hodgkin lymphoma. About 70 participants will receive the drug as part of their regular care and be followed for up to 2 years. The goal is to see if the drug helps prevent …

This study in Japan tracks 250 organ or stem cell transplant patients whose CMV infection did not get better with standard treatments. Patients take Maribavir tablets as part of their normal care, and doctors watch for side effects and check if the virus clears from the blood ove…

This study tests a new oral drug called zasocitinib (TAK-279) for adults with active psoriatic arthritis who have not tried biologic treatments. About 1,088 participants will receive either the new drug, an active comparator, or a placebo for up to 60 weeks. The main goal is to s…

This study looks at how safe and effective the oral drug fruquintinib is for treating advanced colon cancer that hasn't responded to other treatments. It focuses on Black/African American and Hispanic/Latino patients, who were not well-studied in earlier trials. The main goal is …

This study tests a new medicine called TAK-861 for people with narcolepsy type 1, a condition that causes sudden sleep attacks and muscle weakness (cataplexy). About 88 adults will take the drug for a few months, then some will switch to a placebo to see if their symptoms return.…

This study tests the long-term safety of the drug TAK-861 in 500 people with type 1 narcolepsy who have already taken it in earlier trials. Researchers will monitor side effects and measure how well patients can stay awake. The goal is to see if the drug remains safe and effectiv…

This study tests a subcutaneous (under the skin) version of vedolizumab in 70 children with moderate to severe ulcerative colitis or Crohn's disease who already responded to the IV form. The goal is to see how the body handles the drug and if it is safe. Participants receive the …

This study looks at how safe and effective the drug Vonvendi (rVWF) is for children under 18 with von Willebrand disease, a bleeding disorder. Researchers will track side effects and how well the drug controls bleeding over one year. The study is being done in Japan as part of ro…

This study looks at how well the drug teduglutide works for children aged 1 to 17 with short bowel syndrome who rely on IV nutrition. The goal is to see if the drug can reduce the amount of IV nutrition they need, and possibly help some stop it entirely. Researchers will review m…

This study tests whether a new drug, TAK-881, works as well as an existing drug, HYQVIA, for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a nerve disorder causing weakness and numbness. About 59 participants who already receive immunoglobulin ther…

This study looks at the long-term safety and effectiveness of the drug zasocitinib for adults with psoriatic arthritis, a condition causing joint pain and skin problems. About 1,182 people who completed a one-year study on this drug can join and take it daily for up to two more y…

This study tests whether a single dose of TAK-755 is safe and helps people recover after an acute ischemic stroke (a clot blocking blood flow to the brain). About 222 adults aged 18–80 will receive either TAK-755 or a placebo, plus standard stroke care. Researchers will monitor f…

This study tests an oral medication called TAK-279 in people with moderate to severe Crohn's disease, a condition that causes gut inflammation. About 268 adults will receive either one of three doses of TAK-279 or a placebo for 12 weeks to see if it reduces bowel inflammation and…

This study looks at whether vedolizumab can help people with moderate to severe ulcerative colitis or Crohn's disease achieve remission (no symptoms) after 14 weeks of treatment. About 400 adults aged 18 to 80 will receive vedolizumab first as an IV infusion, then as a shot under…

This study looks at how HyQvia, a treatment to boost the immune system, is used in real-world clinics for people with multiple myeloma who have a weakened immune system (secondary immunodeficiency). Researchers will track details like dose, infusion speed, and where the treatment…

This study tests the long-term safety of a drug called mezagitamab for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing easy bruising and bleeding. About 150 participants who were in earlier mezagitamab studies wil…

This study tests whether giving immune globulin (IGI) infusions regularly can prevent serious infections in adults with multiple myeloma who are receiving a type of immunotherapy called bispecific antibody therapy. About 183 participants will be randomly assigned to receive IGI e…

This early-phase study tests whether the experimental drug TAK-781 is safe and tolerable. First, healthy volunteers receive either the drug or a placebo. Then, a small group of people with primary sclerosing cholangitis (PSC) receive the drug. The study also measures how the body…

This study is monitoring the long-term safety and effectiveness of the drug leuprorelin in people with spinal and bulbar muscular atrophy (SBMA), a rare muscle-weakening disease. Researchers will follow about 1,890 patients in routine medical care for up to 8 years, tracking side…

This study tests a new drug called TAK-505 for the first time in people with advanced solid tumors that cannot be removed by surgery. The main goals are to check the drug's safety, find the best dose, and see if it can shrink or slow tumor growth. About 151 adults with certain ca…

This study tests a drug called vedolizumab for people in China with moderate to severe Crohn's disease, a condition that causes inflammation in the gut. About 408 adults will receive either the drug or a placebo to see if it reduces symptoms like belly pain and diarrhea. The goal…

This study tests an investigational drug called elritercept in adults with a bone marrow disorder (MDS) who need regular red blood cell transfusions. The main goal is to see if the drug can help patients go at least 8 weeks without a transfusion. About 225 participants will recei…

This study tests a new oral drug, zasocitinib, for moderate to severe hidradenitis suppurativa (HS), a skin condition causing painful, deep bumps and abscesses. About 90 adults will receive either the drug or a placebo for 4 months, then all will get the drug for up to 8 more mon…

This study tests a daily pill called zasocitinib for adults with nonsegmental vitiligo, a condition where the immune system attacks pigment cells, causing white patches. About 200 participants will receive either the drug or a placebo for up to a year. The goal is to see if the d…

This study tests a drug called vedolizumab in children with chronic pouchitis, an inflammation of an internal pouch created after bowel surgery. About 30 children will receive up to 12 infusions over about 18 months. The goal is to see if the drug can reduce symptoms and pouch in…

This study tests a new medicine called TAK-188 in adults with advanced solid tumors that have not improved with standard treatments. TAK-188 targets and removes certain cells inside tumors that weaken the immune system, potentially allowing the body to fight cancer more effective…

This study aims to see if measuring just one protein function (C1-inhibitor) can accurately diagnose hereditary angioedema (HAE), a rare condition causing sudden swelling. About 514 people in Algeria who are suspected of having HAE or have family members with it will take part. R…

This study tests an experimental drug called TAK-360 in 88 adults with narcolepsy type 2, a condition that causes severe daytime sleepiness. TAK-360 acts like a natural brain chemical that promotes wakefulness. The main goals are to check the drug's safety and see if it helps peo…

This study tests whether the drug vortioxetine can safely reduce depression symptoms in Japanese teenagers aged 12 to 17 with major depressive disorder. About 180 participants will receive either the drug or a placebo daily for 14 weeks, with follow-up for 4 more weeks. The goal …

This study tests a new medicine called TAK-360 for people with idiopathic hypersomnia (IH), a condition that causes extreme sleepiness even after lots of sleep. The drug works like a brain chemical called orexin that helps keep you awake. Researchers want to see if TAK-360 is saf…

This study aims to find out how many people in Spain have been diagnosed with narcolepsy type 1 or type 2, and how many new cases are diagnosed each year. Researchers will review medical records from hospitals across Spain to count patients and understand patterns. The study does…

This study tracks side effects and safety of the drug fruquintinib (Fruzaqla) in 600 adults with colorectal cancer in South Korea. Participants take the drug as prescribed by their doctor. The goal is to see how often side effects occur in everyday use, not to test a new treatmen…

This study observes children aged 2 to 12 with hereditary angioedema (HAE) who are already taking the medication lanadelumab to prevent swelling attacks. Researchers will review medical records to see how long children stay attack-free and how the treatment works in everyday life…

This study looks at how often liver problems happen in Japanese children with Alagille syndrome or progressive familial intrahepatic cholestasis who take the drug Livmarli. Researchers will use a national database to track side effects in about 50 patients. The goal is to better …

This study follows 500 adults with Alpha-1 Antitrypsin Deficiency (AATD) for up to 5 years to understand how liver disease naturally progresses without treatment. Researchers will track liver scarring, complications, and lung function, and use questionnaires to learn about partic…

This study reviews medical records of about 10 adults who had a transplant and developed a difficult-to-treat CMV infection along with severe kidney disease or kidney failure. Researchers want to see how safe the drug maribavir is for these patients. The study does not change the…

This study is observing 600 adults in South Korea who are already receiving vedolizumab injections for ulcerative colitis or Crohn's disease. Researchers will look at medical records to track side effects and how well the treatment works. No new treatments are given—this is just …

This study looks back at medical records of 100 people in Japan with primary immunodeficiency (a weak immune system) who took the drug Cuvitru. The goal is to track serious side effects like allergic reactions, blood clots, and meningitis. No new treatments are given—just a revie…

This study looks at how much of the constipation drug prucalopride gets into breast milk. Twelve breastfeeding women with chronic constipation will provide milk samples over 24 hours. Researchers will also check the growth and development of their babies and ask about any side ef…

This study uses a survey to see how well patients and doctors understand the risks and required checkups for the drug GATTEX, used for Short Bowel Syndrome. About 600 people (patients who have taken GATTEX recently and their doctors) will answer true/false questions online, by ph…

This study looks at whether the dengue vaccine (TDV) reduces the chance of being hospitalized with dengue in children and teens. About 70,000 participants in Thailand, Indonesia, and Malaysia will be followed for 3 years. Researchers will compare hospital stays between those who …